Tony Ho

Company: CRISPR Therapeutics

Job title: EVP, Head of Research & Development

Seminars:

Realizing the Clinical Potential of CRISPR/Cas9 for Best-in-Class Allogeneic Therapies 10:05 am

• Showcase clinical data from CTX110, CTX120 and CTX130 to review how allogeneic cells function in vivo • Analayze depth of response, persistence and durability of the allogeneic cells to achieve complete responses • How do allogeneic cells perform compared to autologous cell therapies?Read more

day: Day Two